药物对比
Erenumab vs Ubrogepant
比较Erenumab（Aimovig，用于预防的注射剂）与Ubrogepant（Ubrelvy，用于急性偏头痛的口服药）。两者均为CGRP拮抗剂，但作用和用途不同。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when evaluating CGRP-targeted options to distinguish monthly preventive therapy from on-demand acute migraine treatment.
结论
Erenumab and Ubrogepant are complementary CGRP therapies rather than direct competitors, with choice driven by prevention versus acute-relief goals.
全部药物对比